Patents Assigned to AstraZeneca
  • Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents
    Patent number: 8148540
    Abstract: The invention relates to new heterocyclic compounds of general formula (I), and their salts with a base or an acid: The invention also relates to a process for the preparation of these compounds as well as their use as medicaments, in particular as anti-bacterial agents.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: April 3, 2012
    Assignee: AstraZeneca
    Inventors: Joseph Aszodi, Maxime Lampilas, Branislav Musicki, David Alan Rowlands, Pascal Colette
  • Polymorph of N,N-diethyl-4-(3-fluorophenyl-piperidin-4-ylidene-methyl)-benzamide hydrochloride salt
    Patent number: 8148406
    Abstract: Polymorphs of N,N-diethyl-4-(3-fluorophenyl-piperidin-4-ylidene-methyl)-benzamide hydrochloride salt, methods of making these polymorphs and uses thereof are described.
    Type: Grant
    Filed: October 5, 2005
    Date of Patent: April 3, 2012
    Assignee: AstraZeneca AB
    Inventors: Simon Nicholas Black, Steve Cook, Louis Joseph Diorazio, James Hulsizer, Gary Moore, Kathryn Quigley
  • Compounds
    Patent number: 8148572
    Abstract: The invention relates to substituted phenylacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: April 3, 2012
    Assignee: AstraZeneca AB
    Inventors: Timothy Jon Luker, Rukhsana Tasneem Mohammed, Stephen Thom, Anil Patel
  • Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease
    Publication number: 20120077813
    Abstract: The present invention relates to a new compound of formula (I) wherein R1 is hydrogen or fluoro; R2 and R3 are independently selected from hydrogen or methyl; or a pharmaceutically acceptable salt thereof, pharmaceutical formulations containing said compound, to the use of said active compound in therapy, to the use for the treatment of conditions associated with glycogen synthase kinase-3 related disorders, such as Alzheimer's disease, as well as for the method of treatment of said disorders, comprising administering to a mammal, including human in need of such treatment, a therapeutically effective amount of said compound.
    Type: Application
    Filed: April 14, 2010
    Publication date: March 29, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Jeremy Nicholas Burrows, Per I. Arvidsson, Erica Tjerneld, Ulrika Yngve
  • N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
    Patent number: 8143408
    Abstract: The present invention relates to new compounds of formula (I) and to pharmaceutical composition containing said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof.
    Type: Grant
    Filed: April 22, 2008
    Date of Patent: March 27, 2012
    Assignee: AstraZeneca AB
    Inventors: Yevgeni Besidski, Inger Kers, Martin Nylöf, Lars Sandberg, Karin Skogholm
  • Therapeutic agents
    Patent number: 8143263
    Abstract: A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: March 27, 2012
    Assignee: Astrazeneca AB
    Inventors: Stuart Norman Lile Bennett, Roger John Butlin, Leonie Campbell, Robert Darren Morse Davies, Graeme Richard Robb, Rolf Peter Walker, Michael James Waring, Helen Claire Pointon, Mikael Dan Brink, Jonas Rickard Fägerhag, Ulrik Jurva, Volker Schnecke, Anette Marie Svensson Henriksson, Christer Ralf Westerlund, Peter Gustaf Bonn
  • Composition for inhalation
    Patent number: 8143239
    Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: March 27, 2012
    Assignee: AstraZeneca AB
    Inventors: Nayna Govind, Maria Marlow
  • Thiazolo (4,5-D) pyrimidine compounds
    Patent number: 8143261
    Abstract: The invention provides certain thiazolopyrimidine compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: March 27, 2012
    Assignee: AstraZeneca AB
    Inventors: Paul Andrew Willis, Roger Bonnert, Simon Fraser Hunt, Iain Alistair Stewart Walters
  • Chemical compounds 572
    Patent number: 8143290
    Abstract: Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: March 27, 2012
    Assignees: AstraZeneca AB, Bayer Schering Pharma Aktiengesellschaft
    Inventors: Markus Berger, Jan Dahmén, Karl Edman, Anders Eriksson, Balint Gabos, Thomas Hansson, Martin Hemmerling, Krister Henriksson, Svetlana Ivanova, Matti Lepistö, Darren McKerrecher, Magnus Munck af Rosenschöld, Stinabritt Nilsson, Hartmut Rehwinkel, Camilla Taflin
  • Methods for Treating Type 2 Diabetes in Patients Resistant to Previous Treatment with other Anti-Diabetic Drugs Employing an SGLT2 Inhibitor and Compositions Thereof
    Publication number: 20120071403
    Abstract: The invention provides methods for treating a patient having type 2 diabetes who has failed on previous regimens of one or more oral and/or injectable anti-diabetic agents, which include the step of administering a therapeutically effective amount of an SGLT2 inhibitor alone or in combination with another anti-diabetic agent and/or other therapeutic agent to such patient. A pharmaceutical composition containing dapagliflozin or dapagliflozin-S-propylene glycol solvate and one or more diabetic agents and/or other therapeutic agents for use in the methods of the invention is also provided.
    Type: Application
    Filed: May 26, 2010
    Publication date: March 22, 2012
    Applicants: ASTRAZENECA UK LIMITED, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul Strumph, Stephanie Moran, James List
  • Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
    Patent number: 8138183
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.
    Type: Grant
    Filed: July 8, 2008
    Date of Patent: March 20, 2012
    Assignee: AstraZeneca AB
    Inventor: Kurt Gordon Pike
  • 8-oxoadenine derivatives acting as modulators of TLR7
    Patent number: 8138172
    Abstract: The present invention provides 8-oxoadenine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The 8-oxoadenine derivatives act as modulators of Toll-like Receptor (TLR) 7 and thus may be used in the treatment of asthma, hepatitis, allergic diseases, viral and bacterial infection as well as cancer.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: March 20, 2012
    Assignees: AstraZeneca AB, Dainippon Sumitomo Pharma Co Ltd.
    Inventors: Anthony Cook, Tom McInally, Stephen Thom, Hiroki Wada
  • COMPOUNDS AND THEIR USES 708
    Publication number: 20120065214
    Abstract: The present invention relates to pyrazinone derivatives of formula (I): wherein R1, R2, R3, R4, R5, R6 and R7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: June 26, 2008
    Publication date: March 15, 2012
    Applicant: AstraZeneca AB
    Inventors: Stephen BROUGH, Richard Evans, Timothy Jon Luker, Piotr Raubo
  • Hydantoin derivatives useful as metalloproteinase inhibitors
    Patent number: 8129412
    Abstract: Formula (I) wherein R1 is a (2-4C)alkyl and is substituted by two or more fluorine groups and R2 is methyl or ethyl, or a pharmaceutically acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by metalloproteinase enzymes.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: March 6, 2012
    Assignee: AstraZeneca AB
    Inventors: David Waterson, David Jonas Persson
  • Chemical compounds
    Patent number: 8129403
    Abstract: This invention relates to novel compounds having the formula (I); and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: March 6, 2012
    Assignee: AstraZeneca AB
    Inventors: Michelle Lamb, Tao Wang, Dingwei Yu, Peter Mohr, Bin Wang
  • Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
    Patent number: 8129393
    Abstract: Compounds of general formula: as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain, depression and anxiety.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: March 6, 2012
    Assignee: AstraZeneca AB
    Inventors: William Brown, Andrew Griffin, Thomas Hudzik, Carla Maciag, Gennady Smagin, Christopher Walpole
  • Phthalazinone derivatives
    Patent number: 8129380
    Abstract: A compound of the formula (I): wherein: A and B together represent an optionally substituted, fused aromatic ring; X and Y are selected from CH and CH, CF and CH, CH and CF and N and CH respectively; RC is selected from H, C1-4 alkyl; and R1 is selected from C1-7 alkyl, C3-20 heterocyclyl and C5-20 aryl, which groups are optionally substituted; or RC and R1 together with the carbon and oxygen atoms to which they are attached form a spiro-C5-7 oxygen-containing heterocyclic group, which is optionally substituted or fused to a C5-7 aromatic ring.
    Type: Grant
    Filed: January 22, 2009
    Date of Patent: March 6, 2012
    Assignee: AstraZeneca AB
    Inventors: Keith Allan Menear, Muhammad Hashim Javaid, Sylvie Gomez, Marc Geoffrey Hummersone, Carlos Fenandez Lence, Niall Morrison Barr Martin, David Alan Rudge, Craig Anthony Roberts, Kevin Blades
  • N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof
    Patent number: 8129391
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: March 6, 2012
    Assignee: AstraZeneca AB
    Inventors: Kevin Michael Foote, Maria-Elena Theoclitou, Andrew Peter Thomas, David Buttar
  • BREATH ACTIVATED INHALER
    Publication number: 20120048272
    Abstract: The disclosure relates to an inhaler, comprising an outlet and a plurality of sealed compartments containing medicament. An opening mechanism is provided to open the compartment presently aligned with the outlet. An indexing mechanism sequentially aligns the compartments with the outlet. A latch is provided for latching the opening mechanism in an energized position. The latch cannot latch the opening mechanism before the indexing mechanism has aligned the next compartment with the outlet. The disclosure also relates to a method of priming an inhaler and a method of dispensing a medicament from an inhaler.
    Type: Application
    Filed: October 7, 2009
    Publication date: March 1, 2012
    Applicant: ASTRAZENECA AB
    Inventors: John Briant, Patrick Campbell, Charles Cooke, Christopher Groombridge, Daniel James John, John Trevor Penhallurick, Nicholas Smartt, Nicholas Harrison, William Bakewell
  • Compounds for the treatment of multi-drug resistant bacterial infections
    Patent number: 8124602
    Abstract: The present invention relates to compounds of Formula V(A): that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds of Formula V(A) useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: February 28, 2012
    Assignee: AstraZeneca AB
    Inventors: Gloria Breault, Charles Joseph Eyermann, Bolin Geng, Marshall Morningstar, Folkert Reck